The FDA’s special fast-track drug program has reportedly been shelved, although the administration insists it is ongoing. Excellent. We have developed a regulatory vehicle so advanced that it can be parked and moving at the same time. Somebody get the transportation secretary.

Reuters, citing six sources and internal documents, reports that the political council overseeing Marty Makary’s priority vouchers has gone dormant. No new vouchers have been awarded since the former commissioner left in May. One source says applications remain open but don’t advance. That is a fast lane in the same sense that a treadmill is an interstate.

HHS says the pilot continues and the FDA is reviewing public feedback to refine it. So the official position is ongoing refinement. You can apparently keep a program alive indefinitely by sanding it.

The pitch was one- or two-month reviews for selected drugs addressing national priorities. And some drugs really did move faster: twelve of twenty-two voucher recipients have been approved, with several gaining eight months or more. Patients getting useful treatments sooner is the point. Nobody needs a political entourage to congratulate itself for discovering that sooner comes before later.

The Daily Heckler: five or six selected stories.
Political satire for your morning inbox.

The question is what the entourage was adding besides entourage.

Reuters reports that recent approvals proceeded without the political council. One cancer drug used the FDA’s existing oncology review machinery. Existing. The bold shortcut has discovered a road that was already on the fucking map.

This is the part where a man sells you a special express route, unfolds a dramatic brochure, and points to the normal entrance. There may be excellent work happening beyond that entrance. It does not follow that the brochure did it.

Career scientists are now overseeing the timelines for nine drugs still in the program, according to Reuters’ sources. The political apparatus is fading; the people doing the actual reviews remain.

Perhaps the next revolutionary pilot could test whether scientists can review medicines without a ceremonial lane being opened over their heads. Give it a bold name. Call it the FDA.